+关注
helen88
暂无个人介绍
IP属地:未知
74
关注
6
粉丝
4
主题
0
勋章
主贴
热门
helen88
2021-06-18
$Sorrento Therapeutics Inc.(SRNE)$
怎么看
helen88
2021-03-09
$游戏驿站(GME)$
挣💰去买SRNE
helen88
2021-02-25
$游戏驿站(GME)$
这谁能想到呢
helen88
2021-02-25
Hihi
helen88
2021-02-09
$Sorrento Therapeutics Inc.(SRNE)$
现在上车还有机会
helen88
2021-01-28
$Sorrento Therapeutics Inc.(SRNE)$
目标越来越近
helen88
2021-01-27
$Sorrento Therapeutics Inc.(SRNE)$
必须见$35
helen88
2020-11-12
这篇文章不错,转发给大家看
Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2
helen88
2020-10-29
有够胆的就是接飞刀最好的时间了。
helen88
2020-09-30
$Sorrento Therapeutics Inc.(SRNE)$
这次上升的更稳
helen88
2020-09-23
$Sorrento Therapeutics Inc.(SRNE)$
看最后一个多小时的增量,你就应该知道上车或下车。
helen88
2020-08-11
$Sorrento Therapeutics Inc.(SRNE)$
终于站上18元
helen88
2020-08-10
$Sorrento Therapeutics Inc.(SRNE)$
我也成绩不错
helen88
2020-06-15
期待行情大反弹。
helen88
2020-06-14
燃石医学开涨43.64%,后面的行情会怎么走呢?
helen88
2020-06-13
惊心动魄的一周在最后半小时给了往后行情一根定海神针。
helen88
2020-06-12
这篇文章不错,转发给大家看
@edward28:很多投资者近两天没有把握好盈利,将挣到手的钱又全部做善事了。
helen88
2020-06-12
心态不好真的别进股市,这过山车的波动一段人怎可承受呀。
helen88
2020-06-11
油股调整到位
helen88
2020-06-10
油股调整到位了吧
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3542328439002885","uuid":"3542328439002885","gmtCreate":1579237855177,"gmtModify":1579237855177,"name":"helen88","pinyin":"helen88","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":74,"tweetSize":70,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.28","exceedPercentage":"93.58%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.78%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":168615926,"gmtCreate":1623973821065,"gmtModify":1623973821065,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>怎么看","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>怎么看","text":"$Sorrento Therapeutics Inc.(SRNE)$怎么看","images":[{"img":"https://static.tigerbbs.com/99037d09bdee63c58835fa40503ef6c3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168615926","isVote":1,"tweetType":1,"viewCount":3251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":329638955,"gmtCreate":1615238608577,"gmtModify":1703486064049,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>挣💰去买SRNE","listText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>挣💰去买SRNE","text":"$游戏驿站(GME)$挣💰去买SRNE","images":[{"img":"https://static.tigerbbs.com/d7c4a38fe80797b37bb4e9d2eb18a442","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/329638955","isVote":1,"tweetType":1,"viewCount":2741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":361313692,"gmtCreate":1614204167416,"gmtModify":1614204167416,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>这谁能想到呢","listText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>这谁能想到呢","text":"$游戏驿站(GME)$这谁能想到呢","images":[{"img":"https://static.tigerbbs.com/5fcf40c3de359990987a137571c6469f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/361313692","isVote":1,"tweetType":1,"viewCount":2304,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":361334736,"gmtCreate":1614203668525,"gmtModify":1614203668525,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":" Hihi","listText":" Hihi","text":"Hihi","images":[{"img":"https://static.tigerbbs.com/8f6dbefd16b3d6760a225e0b498b8b5a","width":"1080","height":"1956"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/361334736","isVote":1,"tweetType":1,"viewCount":1403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":383913118,"gmtCreate":1612828753134,"gmtModify":1703765524356,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>现在上车还有机会","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>现在上车还有机会","text":"$Sorrento Therapeutics Inc.(SRNE)$现在上车还有机会","images":[{"img":"https://static.tigerbbs.com/e5fd2ba5ef4302e557ef6f55cca3798d","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/383913118","isVote":1,"tweetType":1,"viewCount":3722,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":311880162,"gmtCreate":1611774079656,"gmtModify":1703753742849,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>目标越来越近","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>目标越来越近","text":"$Sorrento Therapeutics Inc.(SRNE)$目标越来越近","images":[{"img":"https://static.tigerbbs.com/f4a43d04472d23638348204055645be2","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311880162","isVote":1,"tweetType":1,"viewCount":3054,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":313209913,"gmtCreate":1611716090432,"gmtModify":1703752582217,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>必须见$35","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>必须见$35","text":"$Sorrento Therapeutics Inc.(SRNE)$必须见$35","images":[{"img":"https://static.tigerbbs.com/6d826681b38c8ab6c93ba126180e62d0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/313209913","isVote":1,"tweetType":1,"viewCount":2203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":304942649,"gmtCreate":1605126236481,"gmtModify":1703836347233,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"这篇文章不错,转发给大家看","listText":"这篇文章不错,转发给大家看","text":"这篇文章不错,转发给大家看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/304942649","repostId":"2082718698","repostType":2,"repost":{"id":"2082718698","kind":"news","pubTimestamp":1604930400,"share":"https://www.laohu8.com/m/news/2082718698?lang=&edition=full","pubTime":"2020-11-09 22:00","market":"us","language":"en","title":"Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2082718698","media":"GlobeNewswire","summary":"IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild sympto","content":"<html><body><ul type=\"disc\">\n<li>IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers.</li>\n<li>These initial trials are expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use Authorization).</li>\n<li>Animal model data (golden Syrian hamsters infected with SARS-CoV-2) demonstrated a highly effective neutralizing profile.</li>\n<li>This antibody has been engineered for ultra-high potency, with an expected effective dose in humans to be much lower than current known antibodies being assessed by others in active trials, which would allow for a simple IV-push administration that is suitable in the outpatient setting.</li>\n<li>This antibody has been engineered and validated in preclinical studies to avoid antibody-dependent enhancement (ADE) to potentially increase the safety profile.</li>\n<li>Additional <em>in</em> <em>vitro </em>experiments demonstrated the complete virus neutralizing property of STI-2020 against the highly contagious D614G SARS-CoV-2 variant.</li>\n<li>Sorrento has initiated cGMP manufacturing to produce 100,000 doses, expected to be available early next year, in anticipation of a potential EUA.</li>\n</ul>\n<p>SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous (IV) COVI-AMG (STI-2020) to treat COVID-19 patients with mild symptoms and to evaluate safety and pharmacokinetics in healthy volunteers.</p>\n<p>Sorrento has previously submitted an IND for COVI-GUARD™ (STI-1499), the parent antibody for COVI-AMG. That submission was cleared by the FDA in September. Sorrento has built on the knowledge from the prior IND requirements to file this new IND, including information and data about Sorrento’s affinity maturation process that further enhanced the potency of this antibody.</p>\n<p>As Sorrento previously announced, in preclinical studies, STI-2020 demonstrated a 100% neutralizing effect (both <em>in</em> <em>vitro</em> and <em>in vivo</em>) and at a very low dose prevented SARS-CoV-2 from infecting healthy cells and causing COVID-19-like disease in golden Syrian hamsters.</p>\n<p>The high potency of the antibody may potentially translate to more doses per bioreactor manufacturing run, lower cost per dose, and allow for rapid deployment and availability to patients. Sorrento has initiated cGMP manufacturing to produce 100,000 doses, expected to be available early next year, in anticipation of a potential EUA.</p>\n<p>In order to speed up development toward EUA submission, Sorrento is also planning on initiating dosing in a healthy population in order to rapidly generate safety and pharmacokinetic results.</p>\n<p>The STI-2020 antibody has been evaluated in preclinical studies against multiple strains of SARS-CoV-2, including the highly contagious D614G variant, the current dominant strain globally.</p>\n<p>The STI-2020 antibody has been engineered and demonstrated in preclinical studies to avoid ADE (antibody-dependent enhancement) which may be associated with the serious side effects of some other neutralizing antibodies and vaccines.</p>\n<p>More information about the phase 1 clinical trial can be found on www.clinicaltrials.gov (NCT# NCT04584697).</p>\n<p><strong>About Sorrento Therapeutics, Inc. </strong><br/>Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (\"G-MAB™ library\"), clinical stage immuno-cellular therapies (\"CAR-T\", \"DAR-T™\"), antibody-drug conjugates (\"ADCs\"), and clinical stage oncolytic virus (\"Seprehvir<sup>®</sup>\"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™ and COVI-DROPS™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.</p>\n<p>Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (\"RTX\"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.</p>\n<p>For more information, visit <u>www.sorrentotherapeutics.com</u></p>\n<p><strong>Forward-Looking Statements</strong><br/>This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potency and potential neutralizing profile of STI-2020 and the impact on SARS-CoV-2; the preclinical testing of STI-2020; the safety, pharmacokinetics and efficacy of STI-2020; the potential for STI-2020 to avoid antibody-dependent enhancement side effects; the expectation of the commencement of any pivotal trials for STI-2020; the potential receipt of an EUA for STI-2020 and expected timing for any receipt thereof; the expected availability of doses of STI-2020 and the timing thereof; the belief that the IND addresses all questions and recommendations from the FDA; the predictive value of the animal model used in preclinical studies; the proposed dosages in the phase 1 clinical trial; the potential potency of STI-2020; the expected effective dose in humans; the expected administration method of STI-2020; the potentially faster manufacturing speed, availability and potential lower cost for STI-2020; and Sorrento's potential position in the antiviral industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates' and partners' technologies and prospects and collaborations with partners, including, but not limited to risks related to conducting pre-clinical studies and seeking IND regulatory approval for STI-2020; conducting and receiving results of clinical trials for STI-2020; the clinical and commercial success of STI-2020 against preventing and treating SARS-CoV-2 virus infections; the viability and success of STI-2020 in anti-viral therapeutic areas, including coronaviruses; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 therapeutic product candidates strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.</p>\n<p><strong><u>Contact</u></strong><br/>Alexis Nahama, DVM (SVP Corporate Development)<br/>Email: <u>mediarelations@sorrentotherapeutics.com</u></p>\n<p>Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.<br/>G-MAB™, COVI-GUARD<sup>TM</sup>, COVI-AMG™, COVI-SHIELD™, COVIDTRAP™, T-VIVA-19™, COVI-MAB™, ACE-MAB<sup>TM</sup>, COVI-DROPS<sup>TM</sup>, COVI-TRACK™, COVI-TRACE™, COVI-STIX™, and COVI-MOBILE™ are trademarks of Sorrento Therapeutics, Inc.</p>\n<p>ZTlido® is a trademark owned by Scilex Pharmaceuticals Inc.<br/>All other trademarks are the property of their respective owners. <br/>© 2020 Sorrento Therapeutics, Inc. All Rights Reserved.</p>\n<br/>\n<img height=\"1\" src=\"https://ml.globenewswire.com/release/track/304c722a-046e-41c0-94e8-d4603ebf6fd4\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-11-09 22:00 GMT+8 <a href=https://finance.yahoo.com/news/sorrento-announces-fda-ind-filing-140000531.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers.\nThese initial trials are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sorrento-announces-fda-ind-filing-140000531.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/PoKGHRAaEjCoeUQ7jQhw4g--~B/aD05MzM7dz0yNjU3O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/0La.lfx3M.BOH5N06.8hng--~B/aD05MzM7dz0yNjU3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/04f9f4e64b77331b9d9868e002a03144","relate_stocks":{"SRNE":"索伦托医疗"},"source_url":"https://finance.yahoo.com/news/sorrento-announces-fda-ind-filing-140000531.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2082718698","content_text":"IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers.\nThese initial trials are expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use Authorization).\nAnimal model data (golden Syrian hamsters infected with SARS-CoV-2) demonstrated a highly effective neutralizing profile.\nThis antibody has been engineered for ultra-high potency, with an expected effective dose in humans to be much lower than current known antibodies being assessed by others in active trials, which would allow for a simple IV-push administration that is suitable in the outpatient setting.\nThis antibody has been engineered and validated in preclinical studies to avoid antibody-dependent enhancement (ADE) to potentially increase the safety profile.\nAdditional in vitro experiments demonstrated the complete virus neutralizing property of STI-2020 against the highly contagious D614G SARS-CoV-2 variant.\nSorrento has initiated cGMP manufacturing to produce 100,000 doses, expected to be available early next year, in anticipation of a potential EUA.\n\nSAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous (IV) COVI-AMG (STI-2020) to treat COVID-19 patients with mild symptoms and to evaluate safety and pharmacokinetics in healthy volunteers.\nSorrento has previously submitted an IND for COVI-GUARD™ (STI-1499), the parent antibody for COVI-AMG. That submission was cleared by the FDA in September. Sorrento has built on the knowledge from the prior IND requirements to file this new IND, including information and data about Sorrento’s affinity maturation process that further enhanced the potency of this antibody.\nAs Sorrento previously announced, in preclinical studies, STI-2020 demonstrated a 100% neutralizing effect (both in vitro and in vivo) and at a very low dose prevented SARS-CoV-2 from infecting healthy cells and causing COVID-19-like disease in golden Syrian hamsters.\nThe high potency of the antibody may potentially translate to more doses per bioreactor manufacturing run, lower cost per dose, and allow for rapid deployment and availability to patients. Sorrento has initiated cGMP manufacturing to produce 100,000 doses, expected to be available early next year, in anticipation of a potential EUA.\nIn order to speed up development toward EUA submission, Sorrento is also planning on initiating dosing in a healthy population in order to rapidly generate safety and pharmacokinetic results.\nThe STI-2020 antibody has been evaluated in preclinical studies against multiple strains of SARS-CoV-2, including the highly contagious D614G variant, the current dominant strain globally.\nThe STI-2020 antibody has been engineered and demonstrated in preclinical studies to avoid ADE (antibody-dependent enhancement) which may be associated with the serious side effects of some other neutralizing antibodies and vaccines.\nMore information about the phase 1 clinical trial can be found on www.clinicaltrials.gov (NCT# NCT04584697).\nAbout Sorrento Therapeutics, Inc. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (\"G-MAB™ library\"), clinical stage immuno-cellular therapies (\"CAR-T\", \"DAR-T™\"), antibody-drug conjugates (\"ADCs\"), and clinical stage oncolytic virus (\"Seprehvir®\"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™ and COVI-DROPS™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.\nSorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (\"RTX\"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.\nFor more information, visit www.sorrentotherapeutics.com\nForward-Looking StatementsThis press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potency and potential neutralizing profile of STI-2020 and the impact on SARS-CoV-2; the preclinical testing of STI-2020; the safety, pharmacokinetics and efficacy of STI-2020; the potential for STI-2020 to avoid antibody-dependent enhancement side effects; the expectation of the commencement of any pivotal trials for STI-2020; the potential receipt of an EUA for STI-2020 and expected timing for any receipt thereof; the expected availability of doses of STI-2020 and the timing thereof; the belief that the IND addresses all questions and recommendations from the FDA; the predictive value of the animal model used in preclinical studies; the proposed dosages in the phase 1 clinical trial; the potential potency of STI-2020; the expected effective dose in humans; the expected administration method of STI-2020; the potentially faster manufacturing speed, availability and potential lower cost for STI-2020; and Sorrento's potential position in the antiviral industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates' and partners' technologies and prospects and collaborations with partners, including, but not limited to risks related to conducting pre-clinical studies and seeking IND regulatory approval for STI-2020; conducting and receiving results of clinical trials for STI-2020; the clinical and commercial success of STI-2020 against preventing and treating SARS-CoV-2 virus infections; the viability and success of STI-2020 in anti-viral therapeutic areas, including coronaviruses; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 therapeutic product candidates strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.\nContactAlexis Nahama, DVM (SVP Corporate Development)Email: mediarelations@sorrentotherapeutics.com\nSorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.G-MAB™, COVI-GUARDTM, COVI-AMG™, COVI-SHIELD™, COVIDTRAP™, T-VIVA-19™, COVI-MAB™, ACE-MABTM, COVI-DROPSTM, COVI-TRACK™, COVI-TRACE™, COVI-STIX™, and COVI-MOBILE™ are trademarks of Sorrento Therapeutics, Inc.\nZTlido® is a trademark owned by Scilex Pharmaceuticals Inc.All other trademarks are the property of their respective owners. © 2020 Sorrento Therapeutics, Inc. All Rights Reserved.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":308810328,"gmtCreate":1603922855464,"gmtModify":1703831264929,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"有够胆的就是接飞刀最好的时间了。","listText":"有够胆的就是接飞刀最好的时间了。","text":"有够胆的就是接飞刀最好的时间了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/308810328","isVote":1,"tweetType":1,"viewCount":2691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":977967649,"gmtCreate":1601400234581,"gmtModify":1703824225490,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>这次上升的更稳","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>这次上升的更稳","text":"$Sorrento Therapeutics Inc.(SRNE)$这次上升的更稳","images":[{"img":"https://static.tigerbbs.com/ee5683f2e56fa34b6227645e925a80b5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/977967649","isVote":1,"tweetType":1,"viewCount":2571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":975454378,"gmtCreate":1600807585594,"gmtModify":1703822541962,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>看最后一个多小时的增量,你就应该知道上车或下车。","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>看最后一个多小时的增量,你就应该知道上车或下车。","text":"$Sorrento Therapeutics Inc.(SRNE)$看最后一个多小时的增量,你就应该知道上车或下车。","images":[{"img":"https://static.tigerbbs.com/3e10c19e147f0c6b79deb376c88043f1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/975454378","isVote":1,"tweetType":1,"viewCount":2395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":944486907,"gmtCreate":1597079392409,"gmtModify":1704214350249,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>终于站上18元","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>终于站上18元","text":"$Sorrento Therapeutics Inc.(SRNE)$终于站上18元","images":[{"img":"https://static.tigerbbs.com/0cc815413940745db4a4860346e74e46","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/944486907","isVote":1,"tweetType":1,"viewCount":2168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":944493484,"gmtCreate":1597071442748,"gmtModify":1704214309276,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>我也成绩不错","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>我也成绩不错","text":"$Sorrento Therapeutics Inc.(SRNE)$我也成绩不错","images":[{"img":"https://static.tigerbbs.com/d1c25d50891643ebcf0c1815243ee16b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/944493484","isVote":1,"tweetType":1,"viewCount":1409,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":952471311,"gmtCreate":1592208851733,"gmtModify":1704198251913,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"期待行情大反弹。","listText":"期待行情大反弹。","text":"期待行情大反弹。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952471311","isVote":1,"tweetType":1,"viewCount":1521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952401357,"gmtCreate":1592122184879,"gmtModify":1704198127043,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"燃石医学开涨43.64%,后面的行情会怎么走呢? ","listText":"燃石医学开涨43.64%,后面的行情会怎么走呢? ","text":"燃石医学开涨43.64%,后面的行情会怎么走呢?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/952401357","isVote":1,"tweetType":1,"viewCount":1453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952568771,"gmtCreate":1592028293893,"gmtModify":1704198062641,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","listText":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","text":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/952568771","isVote":1,"tweetType":1,"viewCount":1592,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952851902,"gmtCreate":1591944015406,"gmtModify":1704197676916,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"这篇文章不错,转发给大家看","listText":"这篇文章不错,转发给大家看","text":"这篇文章不错,转发给大家看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952851902","repostId":"952993441","repostType":1,"repost":{"id":952993441,"gmtCreate":1591835131983,"gmtModify":1704197176907,"author":{"id":"3540880674211350","authorId":"3540880674211350","name":"edward28","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3540880674211350","authorIdStr":"3540880674211350"},"themes":[],"htmlText":"很多投资者近两天没有把握好盈利,将挣到手的钱又全部做善事了。","listText":"很多投资者近两天没有把握好盈利,将挣到手的钱又全部做善事了。","text":"很多投资者近两天没有把握好盈利,将挣到手的钱又全部做善事了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952993441","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1518,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952828396,"gmtCreate":1591938857515,"gmtModify":1704197664876,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"心态不好真的别进股市,这过山车的波动一段人怎可承受呀。","listText":"心态不好真的别进股市,这过山车的波动一段人怎可承受呀。","text":"心态不好真的别进股市,这过山车的波动一段人怎可承受呀。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952828396","isVote":1,"tweetType":1,"viewCount":2303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952953640,"gmtCreate":1591857967180,"gmtModify":1704197264337,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"油股调整到位","listText":"油股调整到位","text":"油股调整到位","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952953640","isVote":1,"tweetType":1,"viewCount":1776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":956426756,"gmtCreate":1591775561275,"gmtModify":1704196838756,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3542328439002885","authorIdStr":"3542328439002885"},"themes":[],"htmlText":"油股调整到位了吧","listText":"油股调整到位了吧","text":"油股调整到位了吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/956426756","isVote":1,"tweetType":1,"viewCount":1943,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":313209913,"gmtCreate":1611716090432,"gmtModify":1703752582217,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>必须见$35","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>必须见$35","text":"$Sorrento Therapeutics Inc.(SRNE)$必须见$35","images":[{"img":"https://static.tigerbbs.com/6d826681b38c8ab6c93ba126180e62d0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/313209913","isVote":1,"tweetType":1,"viewCount":2203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":923147816,"gmtCreate":1585808588435,"gmtModify":1704359028188,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CCL\">$嘉年华邮轮(CCL)$</a>买入ccl游轮股是一次高风险又是高回报的大机遇","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CCL\">$嘉年华邮轮(CCL)$</a>买入ccl游轮股是一次高风险又是高回报的大机遇","text":"$嘉年华邮轮(CCL)$买入ccl游轮股是一次高风险又是高回报的大机遇","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/923147816","isVote":1,"tweetType":1,"viewCount":1160,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667803686145","idStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题,可以获得更多曝光哦~如果您想创作优质文章,请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":977967649,"gmtCreate":1601400234581,"gmtModify":1703824225490,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>这次上升的更稳","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>这次上升的更稳","text":"$Sorrento Therapeutics Inc.(SRNE)$这次上升的更稳","images":[{"img":"https://static.tigerbbs.com/ee5683f2e56fa34b6227645e925a80b5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/977967649","isVote":1,"tweetType":1,"viewCount":2571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":927560639,"gmtCreate":1588934295321,"gmtModify":1704178947295,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"今天油价的利好能抵挡历史性最差的非农吗?大家有什么看法,我认为基本大利空已不具备,今晚市场会走好。","listText":"今天油价的利好能抵挡历史性最差的非农吗?大家有什么看法,我认为基本大利空已不具备,今晚市场会走好。","text":"今天油价的利好能抵挡历史性最差的非农吗?大家有什么看法,我认为基本大利空已不具备,今晚市场会走好。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/927560639","isVote":1,"tweetType":1,"viewCount":517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":928899061,"gmtCreate":1586587140753,"gmtModify":1704361739836,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"下周油股应该看多","listText":"下周油股应该看多","text":"下周油股应该看多","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/928899061","isVote":1,"tweetType":1,"viewCount":557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":921740797,"gmtCreate":1586399467719,"gmtModify":1704361168193,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"AAON艾伦建材可留意","listText":"AAON艾伦建材可留意","text":"AAON艾伦建材可留意","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/921740797","isVote":1,"tweetType":1,"viewCount":441,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168615926,"gmtCreate":1623973821065,"gmtModify":1623973821065,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>怎么看","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>怎么看","text":"$Sorrento Therapeutics Inc.(SRNE)$怎么看","images":[{"img":"https://static.tigerbbs.com/99037d09bdee63c58835fa40503ef6c3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168615926","isVote":1,"tweetType":1,"viewCount":3251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":311880162,"gmtCreate":1611774079656,"gmtModify":1703753742849,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>目标越来越近","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>目标越来越近","text":"$Sorrento Therapeutics Inc.(SRNE)$目标越来越近","images":[{"img":"https://static.tigerbbs.com/f4a43d04472d23638348204055645be2","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311880162","isVote":1,"tweetType":1,"viewCount":3054,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":944486907,"gmtCreate":1597079392409,"gmtModify":1704214350249,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>终于站上18元","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>终于站上18元","text":"$Sorrento Therapeutics Inc.(SRNE)$终于站上18元","images":[{"img":"https://static.tigerbbs.com/0cc815413940745db4a4860346e74e46","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/944486907","isVote":1,"tweetType":1,"viewCount":2168,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":952401357,"gmtCreate":1592122184879,"gmtModify":1704198127043,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"燃石医学开涨43.64%,后面的行情会怎么走呢? ","listText":"燃石医学开涨43.64%,后面的行情会怎么走呢? ","text":"燃石医学开涨43.64%,后面的行情会怎么走呢?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/952401357","isVote":1,"tweetType":1,"viewCount":1453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952568771,"gmtCreate":1592028293893,"gmtModify":1704198062641,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","listText":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","text":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/952568771","isVote":1,"tweetType":1,"viewCount":1592,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":953630981,"gmtCreate":1590302537443,"gmtModify":1704192298574,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"港板国安法对全球影响不容勿视","listText":"港板国安法对全球影响不容勿视","text":"港板国安法对全球影响不容勿视","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/953630981","isVote":1,"tweetType":1,"viewCount":1566,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":950886147,"gmtCreate":1589329957289,"gmtModify":1704179884503,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"今年就是各种耍嘴皮。","listText":"今年就是各种耍嘴皮。","text":"今年就是各种耍嘴皮。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/950886147","repostId":"2035604431","repostType":4,"isVote":1,"tweetType":1,"viewCount":594,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":950114726,"gmtCreate":1589289328665,"gmtModify":1704179740210,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$</a>这股估计得百元才能消停","listText":"<a href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$</a>这股估计得百元才能消停","text":"$诺瓦瓦克斯医药(NVAX)$这股估计得百元才能消停","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/950114726","isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":950010367,"gmtCreate":1589149393860,"gmtModify":1704179314863,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"台积电会在五月创新高吗?我认为机会有八成,你认为呢?","listText":"台积电会在五月创新高吗?我认为机会有八成,你认为呢?","text":"台积电会在五月创新高吗?我认为机会有八成,你认为呢?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/950010367","isVote":1,"tweetType":1,"viewCount":484,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":927746822,"gmtCreate":1589065992966,"gmtModify":1704179253257,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"FB应该有一波行情启动","listText":"FB应该有一波行情启动","text":"FB应该有一波行情启动","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/927746822","repostId":"1166051331","repostType":4,"isVote":1,"tweetType":1,"viewCount":530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":927902949,"gmtCreate":1588688478181,"gmtModify":1704178070049,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"今天油股都在涨,不过得小心哦,开始涨跌不一了","listText":"今天油股都在涨,不过得小心哦,开始涨跌不一了","text":"今天油股都在涨,不过得小心哦,开始涨跌不一了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/927902949","isVote":1,"tweetType":1,"viewCount":739,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":924340697,"gmtCreate":1588237225619,"gmtModify":1704367039137,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"看来今年大选各方布局都是拼命把各自的饼画得又大又美","listText":"看来今年大选各方布局都是拼命把各自的饼画得又大又美","text":"看来今年大选各方布局都是拼命把各自的饼画得又大又美","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924340697","isVote":1,"tweetType":1,"viewCount":555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":944493484,"gmtCreate":1597071442748,"gmtModify":1704214309276,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>我也成绩不错","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>我也成绩不错","text":"$Sorrento Therapeutics Inc.(SRNE)$我也成绩不错","images":[{"img":"https://static.tigerbbs.com/d1c25d50891643ebcf0c1815243ee16b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/944493484","isVote":1,"tweetType":1,"viewCount":1409,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":924002462,"gmtCreate":1588162165556,"gmtModify":1704366655891,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3542328439002885","idStr":"3542328439002885"},"themes":[],"htmlText":"赌场是在困景中恢复最快的行业,一半本金在股市,一半就去赌场买一手大小[龇牙] [龇牙] [龇牙] ","listText":"赌场是在困景中恢复最快的行业,一半本金在股市,一半就去赌场买一手大小[龇牙] [龇牙] [龇牙] ","text":"赌场是在困景中恢复最快的行业,一半本金在股市,一半就去赌场买一手大小[龇牙] [龇牙] [龇牙]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924002462","isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}